DOCSLIB.ORG

Application for Inclusion of Fexinidazole in the Who Model List of Essential Medicines (Adult & Children)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application for Inclusion of Fexinidazole in the Who Model List of Essential Medicines (Adult & Children) APPLICATION FOR INCLUSION OF FEXINIDAZOLE IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES (ADULT & CHILDREN) Date: 28-Nov-2018 Total number of pages: 45 Page 1 Application for inclusion in WHO Model List of Essential Medicines 28-Nov-2018 - fexinidazole TABLE OF CONTENTS TITLE PAGE ................................................................................................................................................... 1 TABLE OF CONTENTS .................................................................................................................................. 2 LIST OF TABLES ........................................................................................................................................... 4 LIST OF FIGURES .......................................................................................................................................... 4 ABBREVIATIONS ........................................................................................................................................... 5 1 SUMMARY STATEMENT OF THE PROPOSAL FOR INCLUSION .............................................. 6 2 RELEVANT WHO TECHNICAL DEPARTMENT AND FOCAL POINT (IF APPLICABLE) - NAME OF THE FOCAL POINT IN WHO SUBMITTING OR SUPPORTING THE APPLICATION. ................................................................................................................................ 7 3 NAME OF ORGANIZATION(S) CONSULTED AND/OR SUPPORTING THE APPLICATION ................................................................................................................................. 7 4 INTERNATIONAL NONPROPRIETARY NAME (INN) AND ANATOMICAL THERAPEUTIC CHEMICAL (ATC) CODE OF MEDICINE ............................................................ 7 5 DOSE FORM(S) AND STRENGHTH(S) PROPOSED FOR INCLUSION, INCLUDING ADULT AND AGE APPROPRIATE PAEDIATRIC DOSE FORMS/STRENGTHS ........................ 8 6 WHETHER LISTING IS REQUESTED AS AN INDIVIDUAL OR AS REPRESENTATIVE OF A PHARMACOLOGICAL CLASS ............................................................................................. 9 7 TREATMENT DETAILS (REQUIREMENTS FOR DIAGNOSIS, TREATMENT AND MONITORING) ................................................................................................................................. 9 7.1 THERAPEUTIC INDICATION .......................................................................................................... 9 7.2 POSOLOGY AND METHOD OF ADMINISTRATION ..................................................................... 9 7.2.1 Special populations ........................................................................................................................ 11 7.3 WHO GUIDELINES........................................................................................................................ 11 8 INFORMATION SUPPORTING THE PUBLIC HEALTH RELEVANCE ....................................... 12 8.1 EPIDEMIOLOGY ............................................................................................................................ 12 8.2 ASSESSMENT OF CURRENT USE ............................................................................................. 16 8.3 TARGET POPULATION ................................................................................................................ 19 9 REVIEW OF BENEFITS: SUMMARY OF EVIDENCE OF COMPARATIVE EFFECTIVENESS .......................................................................................................................... 19 Page 2 Application for inclusion in WHO Model List of Essential Medicines 28-Nov-2018 - fexinidazole 9.1 IDENTIFICATION OF CLINICAL EVIDENCE ................................................................................ 19 9.2 SUMMARY OF AVAILABLE DATA ................................................................................................ 20 9.2.1 Primary analysis for efficacy results ............................................................................................... 20 9.2.2 Secondary analyses ....................................................................................................................... 22 9.2.3 Follow-up analysis.......................................................................................................................... 24 10 REVIEW OF HARMS AND TOXICITY: SUMMARY OF EVIDENCE OF SAFETY ...................... 25 10.1 ESTIMATE OF TOTAL PATIENT EXPOSURE TO DATE ............................................................ 25 10.2 DESCRIPTION OF THE ADVERSE EFFECTS/REACTIONS AND ESTIMATES OF THEIR FREQUENCY ................................................................................................................................. 26 10.3 SUMMARY OF AVAILABLE DATA ................................................................................................ 28 10.3.1 Adverse events in clinical trials ...................................................................................................... 28 10.3.1.1 In HAT patients .............................................................................................................................. 29 10.3.1.2 Other patient populations ............................................................................................................... 34 10.3.2 Clinical laboratory data .................................................................................................................. 36 10.3.3 Pregnancy and lactation ................................................................................................................ 36 10.3.4 Interactions ..................................................................................................................................... 37 10.4 SAFETY CONCLUSIONS .............................................................................................................. 39 11 SUMMARY OF AVAILABLE DATA ON COMPARATIVE COST-EFFECTIVENESS OF THE MEDICINE ............................................................................................................................. 40 12 SUMMARY OF REGULATORY STATUS AND MARKET AVAILABILITY OF THE MEDECINE .................................................................................................................................... 40 13 AVAILABILITY OF PHARMACOPOEIAL STANDARDS (BRITISH PHARMACOPOEIA, INTERNATIONAL PHARMACOPOEIA, US PHARMACOPOEAIA, EUROPEAN PHARMACOPOEIA ....................................................................................................................... 41 14 REFERENCES ............................................................................................................................... 42 15 ANNEX ........................................................................................................................................... 45 Page 3 Application for inclusion in WHO Model List of Essential Medicines 28-Nov-2018 - fexinidazole LIST OF TABLES Table 1 - Posology of fexinidazole in adults and children ............................................................................. 10 Table 2 - Summary of current treatment options for HAT ............................................................................. 17 Table 3 - List of studies in the fexinidazole clinical development programme .............................................. 20 Table 4: FEX004 Primary Analysis: Success rate at M18 per randomized treatment group and Non- inferiority test – mITT population ................................................................................................................... 21 Table 5: FEX005 Primary Analysis: Success rate at M12 ............................................................................. 21 Table 6: FEX006 Primary Analysis: Success rate at M12 (ITT population) .................................................. 22 Table 7 – Efficacy outcome at 12 and 18 months after the end of treatment with fexinidazole or NECT (primary efficacy population, clinical efficacy studies in HAT) ....................................................................... 22 Table 8 - Treatment success at 18 months according to baseline CSF-WBC count .................................... 23 Table 9 - Comparison between 18 and 24 months and between primary and follow-up analysis ................ 24 Table 10 - List of studies in the fexinidazole clinical development programme ............................................ 25 Table 11 - Adverse Reactions by decreasing frequency reported in at least 2 patients treated with fexinidazole .................................................................................................................................................... 27 LIST OF FIGURES Figure 1 - fexinidazole structure ...................................................................................................................... 8 Figure 2 – Distribution of cases and risk of T. b. gambiense infection in Africa (2010-2014) ....................... 15 Page 4 Application for inclusion in WHO Model List of Essential Medicines 28-Nov-2018 - fexinidazole ABBREVIATIONS AE: Adverse event ALP: Alkaline phosphatase ALT: alanine aminotransferase AST: aspartate aminotransferase ATC: Anatomical Therapeutic Chemical BBB: Blood Brain Barrier CD: Chagas disease CI: Confidence Interval CNS: Central Nervous System CSF: Cerebrospinal fluid DBL: Database lock DNDi: Drugs for Neglected Diseases initiative DRC: Democratic Republic of Congo ECG:
Load more

Recommended publications
  • Fexinidazole – New Orphan Drug Approval
    Fexinidazole – New orphan drug approval • On July 19, 2021, Sanofi announced the FDA approval of fexinidazole, for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense (T. brucei gambiense) in patients 6 years of age and older and weighing at least 20 kg. — Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count > 100 cells/µL) due to T. brucei gambiense disease, fexinidazole should only be used in these patients if there are no other available treatment options. • Sleeping sickness is a parasitic disease transmitted by the bite of an infected tse-tse fly. It affects mostly populations living in remote rural areas of sub-Saharan Africa. Left untreated, sleeping sickness is almost always fatal. — According to the CDC, less than 100 cases of sleeping sickness have been reported annually to the World Health Organization. Infection of international travelers is rare, but it occasionally occurs and most cases of sleeping sickness imported into the U.S. have been in travelers who were on safari in East Africa. • The efficacy of fexinidazole was established in a randomized, comparative open-label trial in 394 adult patients with late second-stage HAT due to T. brucei gambiense. Patients were randomized to a 10-day treatment regimen of either fexinidazole or nifurtimox-eflornithine combination therapy (NECT). The outcome at 18 months was considered a success if patients were classified as a cure or probable cure. — Success at 18 months was achieved in 91.2% of patients treated with fexinidazole vs.
    [Show full text]
  • Biopharmaceutical Optimization in Neglected Diseases for Paediatric Patients by Applying the Provisional Paediatric Biopharmaceu
    Gonzalez-Alvarez Isabel (Orcid ID: 0000-0002-1685-142X) i. Title (including PI’s name) “Biopharmaceutical Optimization in neglected diseases for paediatric patients by applying the provisional paediatric Biopharmaceutical Classification System” Principal investigator: Gordon L. Amidon Author for correspondence: [email protected] ii. Short running title of less than 40 characters Paediatric Biopharmaceutical Optimization in Neglected Diseases iii. The full names of all authors Jose Manuel del Moral Sanchez (delMoral-Sanchez JM) Isabel Gonzalez Alvarez (Gonzalez-Alvarez I) Aaron Cerda Revert (Cerda-Revert A) Marta Gonzalez Alvarez (Gonzalez-Alvarez M) Andres Navarro Ruiz (Navarro A) Gordon L. Amidon (Amidon GL) Marival Bermejo Sanz (Bermejo M) This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.13650 This article is protected by copyright. All rights reserved. iv. The authors’ institutional affiliations (ie where the work was carried out, with a footnote for an author’s present address if different from where the work was carried out) Jose Manuel del Moral Sanchez (delMoral-Sanchez JM) 1Institute of Molecular and Cellular Biology of Miguel Hernandez University. Avda de la Universidad s/n, 03202 Elche (Alicante) Spain 2Department of Pharmacokinetics and Pharmaceutical Technology,
    [Show full text]
  • Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis
    ORIGINAL RESEARCH published: 13 April 2021 doi: 10.3389/fphar.2021.636265 Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis Valter Viana Andrade-Neto 1, Juliana da Silva Pacheco 1,2, Job Domingos Inácio 1, Elmo Eduardo Almeida-Amaral 1, Eduardo Caio Torres-Santos 1* and Edezio Ferreira Cunha-Junior 1,3* 1Laboratorio de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom, 3Laboratório de Imunoparasitologia, Unidade Integrada de Pesquisa em Produtos Bioativos e Biociencias,ˆ Universidade Federal do Rio de Janeiro, Campus UFRJ-Macaé, Macaé, Brazil Translational studies involving the reuse and association of drugs are approaches that can result in higher success rates in the discovery and development of drugs for serious public health problems, including leishmaniasis. If we consider the number of pathogenic species in relation to therapeutic options, this arsenal is still small, and Edited by: each drug possesses a disadvantage in terms of toxicity, efficacy, price, or treatment Paula Gomes, regimen. In the search for new drugs, we performed a drug screening of L. University of Porto, Portugal amazonensis promastigotes and intracellular amastigotes of fifty available drugs Reviewed by: Manoj Kumar Singh, belonging to several classes according to their pharmacophoric group. Adamas University, India Spironolactone, a potassium-sparing diuretic, proved to be the most promising Adnan Ahmed Bekhit, Alexandria University, Egypt drug candidate. After demonstrating the in vitro antileishmanial activity, we fi *Correspondence: evaluated the ef cacy on a murine experimental model with L.
    [Show full text]
  • Rediscovery of Fexinidazole
    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
    [Show full text]
  • Human African Trypanosomiasis in Non-Endemic Countries (2000-2010)
    1 REVIEW Human African Trypanosomiasis in Non-Endemic Countries (2000–2010) Pere P. Simarro, PhD,∗ Jose´ R. Franco, MD,∗ Giuliano Cecchi, MD,† Massimo Paone, MD,† Abdoulaye Diarra, PhD,‡ Jose´ A. Ruiz Postigo, PhD,§ and Jean G. Jannin, PhD∗ ∗World Health Organization, Control of Neglected Tropical Diseases, Innovativ and Intensified Disease Management, Geneva, Switzerland; †Food and Agriculture Organization of the United Nations (FAO), Animal Production and Health Division, Rome, Italy; ‡World Health Organization, Regional Office for Africa, Brazzaville, Congo; §World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Egypt DOI: 10.1111/j.1708-8305.2011.00576.x Background. Human African trypanosomiasis (HAT) can affect travelers to sub-Saharan Africa, as well as migrants from disease endemic countries (DECs), posing diagnosis challenges to travel health services in non-disease endemic countries (non-DECs). Methods. Cases reported in journals have been collected through a bibliographic research and complemented by cases reported to the World Health Organization (WHO) during the process to obtain anti-trypanosome drugs. These drugs are distributed to DECs solely by WHO. Drugs are also provided to non-DECs when an HAT case is diagnosed. However, in non-DEC pentamidine can also be purchased in the market due to its indication to treat Pneumocystis and Leishmania infections. Any request for drugs from non-DECs should be accompanied by epidemiological and clinical data on the patient. Results. During the period 2000 to 2010, 94 cases of HAT were reported in 19 non-DECs. Seventy-two percent of them corresponded to the Rhodesiense form, whereas 28% corresponded to the Gambiense. Cases of Rhodesiense HAT were mainly diagnosed in tourists after short visits to DECs, usually within a few days of return.
    [Show full text]
  • Pharmacometabolomics of Meglumine Antimoniate in Patients with Cutaneous Leishmaniasis
    Edinburgh Research Explorer Pharmacometabolomics of meglumine antimoniate in patients with cutaneous leishmaniasis Citation for published version: Vargas, DA, Prieto, MD, Martínez-Valencia, AJ, Cossio, A, Burgess, KEV, Burchmore, RJS & Adelaida Gómez, M 2019, 'Pharmacometabolomics of meglumine antimoniate in patients with cutaneous leishmaniasis', Frontiers in pharmacology, vol. 10, 657. https://doi.org/10.3389/fphar.2019.00657 Digital Object Identifier (DOI): 10.3389/fphar.2019.00657 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Frontiers in pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 ORIGINAL RESEARCH published: 20 June 2019 doi: 10.3389/fphar.2019.00657 Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Deninson Alejandro Vargas 1,2, Miguel Dario Prieto
    [Show full text]
  • Nitroaromatic Antibiotics As Nitrogen Oxide Sources
    Review biomolecules Nitroaromatic Antibiotics as Nitrogen Oxide Sources Review Allison M. Rice, Yueming Long and S. Bruce King * Nitroaromatic Antibiotics as Nitrogen Oxide Sources Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; Allison M. Rice , Yueming [email protected] and S. Bruce (A.M.R.); King [email protected] * (Y.L.) * Correspondence: [email protected]; Tel.: +1-336-702-1954 Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; [email protected]: Nitroaromatic (A.M.R.); [email protected] antibiotics (Y.L.) show activity against anaerobic bacteria and parasites, finding * Correspondence: [email protected]; Tel.: +1-336-702-1954 use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the Abstract: Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding usedevelopment in the treatment of new of Heliobacter treatments pylori forinfections, these conditio tuberculosis,ns, the trichomoniasis, associated toxicity human Africanand lack of clear trypanosomiasis,mechanisms of action Chagas have disease limited and their leishmaniasis. therapeutic Despite development. this activity Nitroaro and a clearmatic need antibiotics for require thereductive development bioactivation of new treatments for activity for theseand this conditions, reductive the associatedmetabolism toxicity can convert
    [Show full text]
  • Nifurtimox-Eflornithine Combination Therapy for Second-Stage
    MAJOR ARTICLE Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo Emilie Alirol,1,2,a David Schrumpf,1,2,a Josué Amici Heradi,2 Andrea Riedel,2 Catherine de Patoul,2 Michel Quere,2 and François Chappuis1,2 1 2 Division of International and Humanitarian Medicine, University Hospitals of Geneva, and Médecins Sans Frontières, Operational Centre Geneva, Downloaded from Switzerland Background. Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for pa- tients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program http://cid.oxfordjournals.org/ to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC). Methods. This cohort study included 684 second-stage HAT patients (including 120 children) treated with NECT in Doruma and Dingila hospitals, northeastern DRC, between January 2010 and June 2011. All treatment- emergent adverse events (AEs) were recorded and graded according to the Common Terminology Criteria for Adverse Events version 3.0. Safety and efficacy data were retrieved from the WHO pharmacovigilance forms and from Epitryps, a program monitoring database. by guest on June 13, 2014 Results. Eighty-six percent of the patients experienced at least 1 AE during treatment.
    [Show full text]
  • Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.02.20118000; this version posted June 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Adverse events associated with nifurtimox treatment for Chagas disease in children and adults. A.J. Berenstein**1., N. Falk**2, G. Moscatelli2, S. Moroni2, N. González2, F. Garcia-Bournissen3, G. Ballering2, H.Freilij2, J. Altcheh2+ **Both authors contributed equally + Corresponding author. Affiliations: 1Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), CONICET- GCBA, Laboratorio de Biología Molecular, División Patología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina 2Parasitología, Hospital de Niños Ricardo Gutierrez and Instituto multidisciplinario de Investigación en Patologías Pediátricas -(IMIPP) CONICET-GCBA, Buenos Aires, Argentina 3 Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University. London, Ontario, Canada Keywords: Trypanosoma cruzi, nifurtimox, children, adults, adverse drug reactions Contact information: Email: [email protected] , Telephone: +54 11 4963 4122, Running title: Safety of Nifurtimox for ChD treatment Article’s main point This work shows that children were less affected than adults by ADRs associated with nifurtimox treatment. All the evidence, the incidence, the rate of ADRs and discontinuations suggest that treatment should not be delayed for safety concerns. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.06.02.20118000; this version posted June 5, 2020.
    [Show full text]
  • Sleep Disturbance in MS
    SLEEP DISTURBANCE AND MULTIPLE SCLEROSIS Abbey J. Hughes, PhD Department of Rehabilitation Medicine University of Washington School of Medicine Table of Contents Introduction ................................................................................................................................................................ 2 Summary of MS Sleep Research .......................................................................................................................... 3 Emerging Treatments for Sleep Disturbance in MS .................................................................................... 6 Tips for Assessing Your Sleep – Worksheet .................................................................................................. 8 Additional Tools and Resources.......................................................................................................................... 9 References ................................................................................................................................................................ 10 1 Introduction Multiple sclerosis (MS) is a chronic disease characterized by loss of myelin (demyelination) and damage to nerve fibers (neurodegeneration) in the central nervous system (CNS). MS is associated with a diverse range of physical, cognitive, emotional, and behavioral symptoms, and can significantly interfere with daily functioning and overall quality of life. MS directly impacts the CNS by causing demyelinating lesions, or plaques, in the brain,
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • 2 ? Obesity and Sleep- Disordered Breathing
    Review series Obesity and the lung: 2 ? Obesity and sleep- Thorax: first published as 10.1136/thx.2007.086843 on 28 July 2008. Downloaded from disordered breathing F Crummy,1 A J Piper,2 M T Naughton3 1 Regional Respiratory Centre, ABSTRACT include excessive daytime sleepiness, unrefreshing Belfast City Hospital, Belfast, 2 As the prevalence of obesity increases in both the sleep, nocturia, loud snoring (above 80 dB), wit- UK; Royal Prince Alfred developed and the developing world, the respiratory nessed apnoeas and nocturnal choking. Signs Hospital, Woolcock Institute of Medical Research, University of consequences are often underappreciated. This review include systemic (or difficult to control) hyperten- Sydney, Sydney, New South discusses the presentation, pathogenesis, diagnosis and sion, premature cardiovascular disease, atrial fibril- Wales, Australia; 3 General management of the obstructive sleep apnoea, overlap and lation and heart failure.8 The obstructive sleep Respiratory and Sleep Medicine, obesity hypoventilation syndromes. Patients with these apnoea syndrome (OSAS) is arbitrarily defined by Department of Allergy, Immunology and Respiratory conditions will commonly present to respiratory physi- .5 apnoeas or hypopnoeas per hour plus symp- Medicine, Alfred Hospital and cians, and recognition and effective treatment have toms of daytime sleepiness. Monash University, Melbourne, important benefits in terms of patient quality of life and Almost 20 years ago the prevalence of OSA and Victoria, Australia reduction in healthcare
    [Show full text]